Ongoing Projects

HOME > R&D Pipeline > Current status > Ongoing Projects

KDDF-201812-20 Development of A Novel Small Molecule Inhibitor for Idiopathic Pulmonary Fibrosis (IPF) Treatment(Respiratory Diseases, Chemical) [2019-09-27]

PRINT
Ongoing Project
Section Lead
Generation
Lead
Optimization
Preclinical Phase I Phase II Phase III

Development and Market Objectives

To develop a novel treatment for Idiopathic Pulmonary Fibrosis(IPF) via inhibition of collagen synthesis targeting Prolyl-tRNA synthetase(PRS)

Unmet Medical Need & Target Patients

Target Patients:

Over 50 years old, mild to moderate patients who are diagnosed with pulmonary fibrosis by high resolution CT (HRCT) or biopsy, and whose forced vital capacity (FVC) is within 50~80%

 

Unmet Medical Needs:

Patients who suffer from IPF typically succumbed to death in 3 to 5 years after diagnosis. Unfortunately, the current standard of care merely attenuates progression of the disease, yet unable to halt fibrosis. Therefore, there are significant unmet needs for development of innovative and effective treatment to stop progression of IPF (by inhibiting excessive deposition of ECM proteins and inflammation).

Status

- Identification of Prolyl-tRNA Synthetase(PRS) as a crucial enzyme for collagen synthesis

- Target validation in pulmonary fibrosis animal models and IPF patient lung tissues

- Confirmation of efficacy in Bleomycin-induced mouse pulmonary fibrosis models (prophylactic & therapeutic)

- Completion of 4-week GLP toxicity study

- Optimization of DWN12088 process chemistry and API manufacturing

 

 

Intellectual Property

-  PCT application (monopoly period until 2037)

-  Plans for expanding into manufacturing methods, compositions, formulations, and new applications.

Competitive Advantages

1. DWN12088 is a first-in-class PRS inhibitor, which has shown superior anti-fibrotic efficacy in pulmonary fibrosis animal models compared to reference compounds. DWN12088 was developed using X-ray co-crystallography of recombinant PRS protein and the compound (structure-based drug design). Currently there is no pipeline directly inhibits collagen, which is a pathological hallmark in fibrosis.

2. Highly selective and specific inhibition of PRS to decrease collagen production, and wide safety margin

3. Expandable to various fibrotic indications in addition to lung (liver, heart, kidney, skin, etc.)

Contact & Company Overview

Related Project

Related Project
list
Update to 2013 © KOREA DRUG DEVELOPMENT FUND. ALL RIGHTS RESERVED. QR Code